{"filing":{"accession_number":"0001104659-26-075151","cik":"0001781983","ticker":"APRE","company_name":"Aprea Therapeutics, Inc.","form":"8-K","filing_date":"2026-06-17","report_date":null,"primary_document":"tm2618205d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1781983/000110465926075151/tm2618205d1_8k.htm"},"events":[{"id":11562,"run_id":10152,"accession_number":"0001104659-26-075151","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"This Item 5.07 disclosure reports the results of Aprea Therapeutics' 2026 annual meeting of stockholders held on June 16, 2026, including voting outcomes on six proposals: election of three Class I directors (Marc Duey, Richard Peters, M.D., and Bernd R. Seizinger, M.D., Ph.D.), ratification of EisnerAmper LLP as auditor, approval of a reverse stock split authorization (1-for-3 to 1-for-8 ratio), advisory votes on executive compensation and compensation vote frequency, and adjournment authority. The reverse stock split authorization is particularly material as it grants the Board discretion to implement a significant capital structure change that would affect all shareholders.","company_name":"Aprea Therapeutics, Inc.","ticker":"APRE","filing_date":"2026-06-17","submitted_at":null,"items":[{"id":8178,"accession_number":"0001104659-26-075151","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This Item 5.07 disclosure reports the results of Aprea Therapeutics' 2026 annual meeting of stockholders held on June 16, 2026, including voting outcomes on six proposals: election of three Class I directors (Marc Duey, Richard Peters, M.D., and Bernd R. Seizinger, M.D., Ph.D.), ratification of EisnerAmper LLP as auditor, approval of a reverse stock split authorization (1-for-3 to 1-for-8 ratio), advisory votes on executive compensation and compensation vote frequency, and adjournment authority. The reverse stock split authorization is particularly material as it grants the Board discretion to implement a significant capital structure change that would affect all shareholders.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-17T20:17:10.899174+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":8178,"accession_number":"0001104659-26-075151","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This Item 5.07 disclosure reports the results of Aprea Therapeutics' 2026 annual meeting of stockholders held on June 16, 2026, including voting outcomes on six proposals: election of three Class I directors (Marc Duey, Richard Peters, M.D., and Bernd R. Seizinger, M.D., Ph.D.), ratification of EisnerAmper LLP as auditor, approval of a reverse stock split authorization (1-for-3 to 1-for-8 ratio), advisory votes on executive compensation and compensation vote frequency, and adjournment authority. The reverse stock split authorization is particularly material as it grants the Board discretion to implement a significant capital structure change that would affect all shareholders.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-17T20:17:10.899174+00:00","company_name":"Aprea Therapeutics, Inc.","ticker":"APRE","filing_date":"2026-06-17"}]}